<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: page no/section/legend)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Neuropathological evaluations section, page 21-22	

Cell materials	Yes (indicate where provided: page no/section/legend)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		x
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		Х

Experimental animals	Yes (indicate where provided: page no/section/legend)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		х
Animal observed in or captured from the field: Provide species, sex and age where possible		х
Model organisms: Provide Accession number in repository (where relevant) OR RRID		Х

Plants and microbes	Yes (indicate where provided: page no/section/legend)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		x
Microbes: provide species and strain, unique accession number if available, and source		Х

Human research participants	Yes (indicate where provided: page no/section/legend)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Manuscript text, materials and methods, page 20: "The study was approved by the Mayo Clinic IRB. All participants provided written informed consent to participate in this study." IRB numbers: 17-010087, 17-002468, 15-008682, 15-004618, 712-98, 14-004401, 08-005553"	
Provide statement confirming informed consent obtained from study participants.	Manuscript text, materials and methods, page 20: "The study was approved by the Mayo Clinic IRB. All participants provided written informed consent to participate in this study."	
Report on age and sex for all study participants.	Table 1	

<u>Design</u>

Study protocol	Yes (indicate where provided: page no/section/legend)	n/a
For clinical trials, provide the trial registration		.,
number OR cite DOI in manuscript.		Х

Yes (indicate where provided: page no/section/legend)	n/a
	Χ
	Yes (indicate where provided: page no/section/legend)

Experimental study design (statistics details)	Yes (indicate where provided: page no/section/legend)	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination		Х
Randomisation		Χ
Blinding		Х
Inclusion/exclusion criteria	The inclusion/exclusion criteria are given on page 20.	

Sample definition and in-laboratory replication	Yes (indicate where provided: page no/section/legend)	n/a
State number of times the experiment was replicated in laboratory		х
Define whether data describe technical or biological replicates		x

Ethics	Yes (indicate where provided: page no/section/legend)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Manuscript text, materials and methods, page 20: "The study was approved by the Mayo Clinic IRB. All participants provided written informed consent to participate in this study." IRB numbers: 17-010087, 17-002468, 15-008682, 15-004618, 712-98, 14-004401, 08-005553"	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		х
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		х

If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	х

<u>Analysis</u>

Attrition	Yes (indicate where provided: page no/section/legend)	n/a
State if sample or data point from the analysis is	No information was excluded during the analyzes.	Χ
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: page no/section/legend)	n/a
Describe statistical tests used and justify choice of tests.	Statistical methods are provided in the "statistical analysis" section of the manuscript. Generalized additive models (GAMs) were used to model how mean log-transformed tau PET SUVR varies with numeric Thal phase and numeric Braak stage.	

Data Availability	Yes (indicate where provided: page no/section/legend)	n/a
State whether newly created datasets are available,	Data and materials availability section: "All data	
including protocols for access or restriction on	associated with this study are available in the Dryad	
access.	repository"	
	, ,	
If data are publicly available, provide accession	https://doi.org/10.5061/dryad.v6wwpzh48	
number in repository or DOI or URL.	1111ps.//doi.org/10.3001/drydd.vowwpzn40	
If publicly available data are reused, provide		
accession number in repository or DOI or URL, where		
possible.		
		X
		Α

Code Availability	Yes (indicate where provided: page no/section/legend)	n/a
For all newly generated code and software essential		V
for replicating the main findings of the study:		^
State whether the code or software is available.		
If code is publicly available, provide accession		
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: page no/section/legend)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		v
endorsed through community initiatives. Journals		^
have their own policy about requiring specific		

guidelines and recommendations to complement MDAR.	
State if relevant guidelines (eg., ICMJE, MIBBI,	X
ARRIVE) have been followed, and whether a checklist	1
(eg., CONSORT, PRISMA, ARRIVE) is provided with	
the manuscript.	